http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2576844-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f7b665fb8f15d0e2b0911539d39f8a2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 2011-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05909e3833fd7d49b87cfd17c10f6f7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb15439b5779fefcbd28dc6462a52df1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_184eefc8e6268fcbe7a47b57c74d7605 |
| publicationDate | 2016-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2576844-T3 |
| titleOfInvention | Sigma Ligands for Use for Prevention and / or Treatment of Postoperative Pain |
| abstract | Sigma ligand for use in the prevention and / or treatment of pain developed as a consequence of surgery, the sigma ligand having the general formula (I): ** Formula ** in which R1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl , -COR8, -C (O) OR8, -C (O) NR8R9, -CH> = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, - NR8C (O) R9, -NO2, -N> = CR8R9, and halogen; R2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl, Substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH> = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8 , -NR8R9, -NR8C (O) R9, -NO2, -N> = CR8R9 and halogen; R3 and R4 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or non-aromatic or aromatic heterocyclyl unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH> = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, -NR8C (O) R9, -NO2, -N> = CR8R9 and halogen, or together form an optionally substituted fused ring system; R5 and R6 are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR8, -C (O) OR8, -C (O) NR8R9, -CH> = NR8, -CN, -OR8, -OC (O) R8, -S (O) t-R8, -NR8R9, -NR8C (O) R9, -NO2, -N> = CR8R9 and halogen, or together they form, with the nitrogen atom to which they are attached, an aromatic or non-aromatic heterocyclyl group, substituted or not replaced; n is selected from 1, 2, 3, 4, 5, 6, 7, and 8; t is 1, 2, or 3; R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy substituted, substituted or unsubstituted aryloxy and halogen; or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof. |
| priorityDate | 2010-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 862.